HL-085 for adults with neurofibromatosis type 1 and inoperable plexiform neurofibromas
Tests HL-085 in adults with neurofibromatosis type 1 and plexiform neurofibromas that cannot be removed.
Key facts
- Who runs it
- Shanghai Kechow Pharma, Inc.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 70 people, planned
- Started
- 18 Oct 2021
- Expected to end
- 31 Oct 2028
- Type of study
- Interventional
- Treatments tested
- HL-085
- Record updated
- 31 May 2023
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with neurofibromatosis type 1 (NF1) who have plexiform neurofibromas that cannot be removed by surgery and cause symptoms. All take the drug HL-085 by mouth.
- Age
- 18 to 80 years
- Sex
- All sexes
- Disease stage
- Plexiform neurofibromas (nerve tumours) that cannot be operated on and cause symptoms. At least one tumour must be at least 3 cm (1.2 in) long and visible on MRI. Daily activity level (ECOG) of 0-2.
- Earlier treatment
- No earlier treatment with MEK 1/2 inhibitors. No surgery within 4 weeks or radiotherapy within 6 weeks before joining. No other trial treatment within 4 weeks.
- Biomarker or test result
- An NF1 gene change, or at least 1 NF1 sign, such as ≥6 cafe-au-lait spots, freckles in the armpit or groin, ≥2 Lisch nodules, typical bone changes, an optic pathway glioma, or a parent, child or sibling with NF1.
Main reasons for not taking part
- Cannot have MRI scans, or tumours cannot be checked by MRI
- Cannot take pills by mouth or has trouble swallowing
- Past or current retina disease, such as retinal vein occlusion
- Organs not working well enough, infections or other uncontrolled disease
- Allergy to the study drug or similar drugs
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Age: patients must be ≥18 years of age at the time of study entry
- Diagnosis: Patients must have inoperable and symptomatic plexiform neurofibromas(PN), and patients must have NF1 mutation or meet at least 1 of the following NF1 diagnostic criteria:; ① ≥6 cafe-au-lait macules ; ② Axillary freckling or freckling in inguinal regions; ③ ≥2 Lisch nodules (iris hamartomas); ④ A distinctive bony lesion such as dysplasia of the sphenoid bone or dysplasia or thinning of long bone cortex); ⑤ An optic pathway glioma; ⑥ First-degree relative with NF1
- Patients must have a measurable lesion, defined as at least 3 cm in length, amenable to MRI for efficacy assessment
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- Patients are able to understand and voluntarily sign a written informed consent form
- Patients must be willing and able to complete study procedures and follow-up examinations
Who cannot take part
- Patients who are unable to take drugs orally, have difficulty swallowing or anything that may lead to inadequate drug absorption
- Prior treatment with MEK 1/2 inhibitors
- Patients with previous or current retinal diseases such as retinal vein occlusion (RVO), retinal pigment epithelium detachment (RPED), central serous retinopathy (CSR), etc. (except retinopathy caused by research diseases)
- Strong CYP2C9 inhibitors or inducers within 7 days before treatment of the study drug
- Patients who received surgery within 4 weeks or radiotherapy within 6 weeks before enrollment
- Patients who participated in any other clinical study treatment within 4 weeks before enrollment
- Patients treated with anti-NF1 treatment with unresolved chronic toxicity
- Patients known to be allergic to the ingredients or analogues of the study drug
- With infections or other uncontrolled disease
- Patients who are unable to undergo MRI scans (prosthesis, prosthesis, braces, etc.) or patients with lesions that cannot be evaluated by MRI
- Patients do not have adequate organ function
- Clinical judgment by the investigator that the patient should not participate in the study
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a Multi-center, Open-label, Single-arm Phase II Study to Evaluate the Efficacy and Safety of HL-085 in the treatment of Adult Participants with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas(PN)
The group in the trial
- HL-085Treatment being tested
HL-085 9mg BID
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multi-center, Open-label, Single-arm Phase II Study to Evaluate the Efficacy and Safety of HL-085 in the Treatment of Adult Participants With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
- Plain-language title
- HL-085 for adults with neurofibromatosis type 1 and inoperable plexiform neurofibromasGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Fit questions
- Built from NCT05331105, who can take part
- Record updated
- 31 May 2023